These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37632299)

  • 1. Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors.
    Freitas de Sousa FJ; Nunes Azevedo FF; Santos de Oliveira FL; Vieira Carletti J; Freire VN; Zanatta G
    J Biomol Struct Dyn; 2024 Nov; 42(18):9283-9293. PubMed ID: 37632299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.
    Bian X; Dong W; Zhao Y; Sun R; Kong W; Li Y
    J Mol Model; 2014 Apr; 20(4):2166. PubMed ID: 24633771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Dynamics Simulations to Investigate the Binding Mode of the Natural Product Liphagal with Phosphoinositide 3-Kinase α.
    Gao Y; Ma Y; Yang G; Li Y
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27367663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.
    Li Y; Zhang J; He D; Liang Q; Wang Y
    J Mol Model; 2012 May; 18(5):1907-16. PubMed ID: 21870199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.
    Shafiq M; Sherwani ZA; Mushtaq M; Nur-E-Alam M; Ahmad A; Ul-Haq Z
    Mol Divers; 2024 Aug; 28(4):1907-1924. PubMed ID: 38305819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors.
    Nunes Azevedo FF; Freitas de Sousa FJ; Santos de Oliveira FL; Vieira Carletti J; Zanatta G
    J Biomol Struct Dyn; 2023 Feb; 41(3):1085-1097. PubMed ID: 34913837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based pharmacophore modeling and DFT studies of Indian Ocean-derived red algal compounds as PI3Kα inhibitors.
    Vasuki A; Christy HJ; Renugadevi K; Dammalli M
    Mol Divers; 2024 Aug; 28(4):2563-2581. PubMed ID: 37466805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational Design of a Novel 6
    Shi X; Feng H; Tian H; Ma H; Pang X; Mao C; Xiang P; Xu Z; Han W; Yan Y; Chen W; Nan Y; Nan G; Hu Z; Hui L; Li C; Li Y
    J Med Chem; 2024 Sep; 67(17):15387-15410. PubMed ID: 39159497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach.
    Zhu J; Li X; Meng H; Jia L; Xu L; Cai Y; Chen Y; Jin J; Yu L; Gao M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8172-8183. PubMed ID: 37572326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
    Sabbah DA; Simms NA; Brattain MG; Vennerstrom JL; Zhong H
    Bioorg Med Chem Lett; 2012 Jan; 22(2):876-80. PubMed ID: 22212721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
    Fairhurst RA; Imbach-Weese P; Gerspacher M; Caravatti G; Furet P; Zoller T; Fritsch C; Haasen D; Trappe J; Guthy DA; Arz D; Wirth J
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3569-74. PubMed ID: 26206504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel potential PI3Kα inhibitors for cancer therapy.
    Zhang Q; Sang F; Qian J; Lyu S; Wang W; Wang Y; Li Q; Du L
    J Biomol Struct Dyn; 2021 Jul; 39(10):3721-3732. PubMed ID: 32425109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of high-affinity pyridoxal kinase inhibitors targeting cancer therapy: an integrated docking and molecular dynamics simulation approach.
    Banerjee P; Chandra A; Mohammad T; Singh N; Hassan MI; Qamar I
    J Biomol Struct Dyn; 2024 Oct; 42(16):8523-8540. PubMed ID: 37578056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical analogue based drug design for cancer treatment targeting PI3K: integrating machine learning and molecular modeling.
    Bazuhair MA; Alghamdi AA; Baothman O; Afzal M; Alzarea SI; Imam F; Moglad E; Altayb HN
    Mol Divers; 2024 Aug; 28(4):2345-2364. PubMed ID: 39154146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinostide 3-kinase (PI3Kα).
    Sabbah DA; Saada M; Khalaf RA; Bardaweel S; Sweidan K; Al-Qirim T; Al-Zughier A; Halim HA; Sheikha GA
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3120-4. PubMed ID: 26099539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.